Plasma concentrations of cross linked fibrin degradation products, a marker of intravasculail thrombosis and fibrinolysis, were measured in 495 patients with suspected pulmonary embolism referred for ventilation-perfusion lung scanning to determine whether concentrations are increased in pulmonary embolism and their potential use in diagnosis. Lung scans were described as normal (n = 66) or as showing a low (n = 292), indeterminate (n = 58), or high probability (n = 79) of pulmonary embolism. There was a difference between the mean levels of cross linked fibrin degradation products in each scan category: normal scans, 142 ng/ml; low probability scans, 295 ng/ml; indeterminate probability scans, 510 ng/ ml; high probability scans, 952 ng/ml (p < 0-001 
lysis, were measured in 495 patients with suspected pulmonary embolism referred for ventilation-perfusion lung scanning to determine whether concentrations are increased in pulmonary embolism and their potential use in diagnosis. Lung scans were described as normal (n = 66) or as showing a low (n = 292), indeterminate (n = 58), or high probability (n = 79) of pulmonary embolism. There was a difference between the mean levels of cross linked fibrin degradation products in each scan category: normal scans, 142 ng/ml; low probability scans, 295 ng/ml; indeterminate probability scans, 510 ng/ ml; high probability scans, 952 ng/ml (p < 0-001). Of the patients with high probability scans, 96% had raised con tilation-perfusion scan (11); ventilation-perfusion scan films not available for review (12) . Data were analysed by analysis of variance, t tests, and Fisher's exact test. The distribution of the concentrations of cross linked fibrin degradation products was skewed, so all analyses were conducted on data transformed to loge.
Results
Of the 495 scans, 66 were considered to be normal; 292 were considered to have a low, 58 an indeterminate, and 79 a high probability of pulmonary embolism. The mean concentration of cross linked fibrin degradation products increased in each lung scan diagnostic category as the probability of pulmonary embolism increased. Mean concentrations ranged from 142 ng/ml in patients with a normal scan to 952 ng/ml in patients with a high probability scan (F = 47 0, 3,491 df; p < 0-001) (figure). The mean concentration of cross linked fibrin degradation products in the group with a high probability scan was significantly higher than that of the other diagnostic groups combined (F = 11 4, 1,493 df; p < 0001).
There was no difference between mean concentrations of cross linked fibrin degradation products in inpatients and in outpatients in the group as a whole, though inpatients with a normal or low probability scan had higher concentrations than outpatients in this group (inpatients 361 ng/ml, outpatients 185 ng/ml; t = 6 41, 356 df, p < 0 001).
Seventy six of 79 patients (960o) with a lung scan with a high probability of pulmonary embolism had concentrations of cross linked fibrin degradation products greater than the normal range of 0-250 ng/ml. Raised concentrations were also seen in 179 of 350 patients (4300) with scans having a low or indeterminate probability of pulmonary embolism. The underlying conditions in these patients are listed in table 2. Substantially increased concentrations could be attributed to another condition in 8500 of cases, but mild increases (250-400 ng/ml) were unexplained.
In patients with a high probability lung scan the mean concentrations of cross linked fibrin degradation products in patients receiving heparin at presentation for the scan was lower (842 ng/ml) than the concentrations in patients not receiving heparin (1088 ng/ml), but the difference was not significant. with normal concentrations of cross linked fibrin degradation products fall within the accepted range of possible error in the lung scan diagnosis. A further possible explanation for normal or borderline increases in cross linked fibrin degradation products in patients with a high probability of pulmonary embolism according to the scan relates to heparin treatment. Heparin inhibited the generation of fibrin degradation products after experimental pulmonary embolism in dogs, probably by inhibiting systemic fibrin formation.2' Although the mean concentration of cross linked fibrin degradation products in patients receiving heparin at the time of scanning did not differ from that of the patients not receiving it, six of seven patients with a high probability lung scan and low concentrations of the fibrin degradation products (less than 400 ng/ml) were being treated with heparin. Concentrations of cross linked fibrin degradation products were raised in 43% of patients with normal, low, or indeterminate probability scans. This was anticipated and two explanations are offered. The issue of the accuracy of lung scan diagnosis has already been raised. Whereas a normal perfusion scan is generally agreed to exclude pulmonary embolism, the interpretation of an abnormal perfusion scan is less straightforward.2224 The incidence of pulmonary embolism, as diagnosed subsequently from the pulmonary angiogram, in patients with lung scans having a low probability of pulmonary embolus is 10% and in those with indeterminate probability scans 25 % . Increased cross linked fibrin degradation products in patients with a negative ventilation-perfusion scan may also occur if they are derived from another source of intravascular fibrin. The assay is very sensitive to the products of lysis (1 ng/ml) and although specific for that process it is not specific for disease category. The disorders listed in table 2 are known to be complicated by intravascular fibrin deposition and its attendant lysis.
Reports'7 18 on the use of measurements of cross linked fibrin degradation products in the diagnosis of pulmonary embolism have produced conflicting results. Goldhaber et al'7 measured concentrations of cross linked fibrin degradation products in patients with a normal lung scan and positive pulmonary angiograms (positive diagnosis) and concluded that increased concentrations were not an accurate marker of pulmonary embolism. The quoted sensitivity (89%) was, however, similar to the accepted sensitivity of a high probability lung scan and pulmonary angiogram. 22 The high percentage of patients in their study with a normal scan and raised concentrations of cross linked fibrin degradation products without apparent cause is contary to our experience.
Others have claimed high sensitivity (100%) and specificity (81%) and proposed a direct correspondence between concentrations of these fibrin degradation products and risk of pulmonary embolism. '8 Our experience with a large study group indicates that, despite statistically different mean concentrations in the lung scan diagnostic groups, the range of values is such that cross linked fibrin degradation product concentration alone in an individual patient is insufficient to determine the risk of pulmonary embolism. The positive predictive value of the test-that is, in predicting a high probability scan-is only 26%. The negative predictive value of the test is, however, high (9855%).
Lung scans of low or indeterminate probability may be insufficient grounds for excluding pulmonary embolism. 23 24 Although pulmonary angiography would help in these cases, it may not be practical. Seventy one per cent of scans in this series were in these categories. Measurement of cross linked fibrin degradation products might prove a useful adjunct in this setting and deserves further study in conjunction with angiography. Normal concentrations in a promptly drawn blood sample before anticoagulation should increase confidence in a lung scan diagnosis of low probability of pulmonary embolism, and a raised concentration without other explanation in patients with a scan having a low or indeterminate probability of pulmonary embolism increases the probability of pulmonary embolism. Although concentrations of cross linked fibrin degradation products offer insights into the pathogenesis of pulmonary embolism and may yet be of clinical use, measurement of their concentration without reference to the patient's clinical state cannot be recommended as a discriminatory test for pulmonary embolism.
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